Skip to main content

Advertisement

Table 1 Table 1

From: Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis

MP4002 SAR study (14 days)     
  MP29-02* (n=207) FP (n=207) AZE (n=208) Placebo (n=210)
TRAE n (%) 17 (8.2%) 14 (6.8%) 16 (7.7%) 8 (3.8%)
Dysgeusia 5 (2.4%) 2 (1.0%) 7 (3.4%) 1 (0.5%)
Epistaxis 2 (1.0%) 5 (2.4%) 4 (1.9%) 2 (1.0%)
Headache 1 (0.5%) 5 (2.4%) 1 (0.5%) 3 (1.4%)
Chronic rhinitis study (52 weeks)     
  MP29-02* (n=404) FP (n=207)   
TRAE n (%) 38 (9.4%) 23 (11.1%)   
Dysgeusia 10 (2.5%) 1 (0.5%)   
Epistaxis 5 (1.2%) 1 (0.5%)   
Headache 4 (1.0%) 9 (4.3%)